Bile Duct Cancer Treatment: Surgery to Targeted Therapy

Every treatment plan for bile duct cancer starts with one word. Resectable means the whole tumor can be taken out by surgery. Unresectable means it cannot.

Location decides that more than size does. NCI's clinical summary reports that total resection is possible in 25% to 30% of tumors starting in the distal bile duct, near the intestine. The rate is lower for tumors higher up, closer to the liver. Bile ducts sit next to major blood vessels, and tumors there can spread along the duct inside the liver.

There are three locations, and each has its own operation:

• Intrahepatic — inside the liver. Treated with partial hepatectomy, removing the part of the liver holding the tumor. That may be a wedge, a whole lobe, or more.
• Perihilar — at the point where the ducts join outside the liver. Also called a Klatskin tumor. Removing the duct alone leaves high local recurrence rates. Adding a partial hepatectomy that includes the caudate lobe has improved long-term results, and reported 5-year survival with that approach runs 20% to 50%.
• Distal — near the small intestine. Treated with a Whipple procedure, removing the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct. Enough pancreas is left to make digestive juices and insulin. This is the location where complete removal is most often achievable.

If you are still working out which type you have, our page on bile duct cancer stages explains how it is described.

Chemotherapy after surgery is called adjuvant therapy. Its value here is real but modest, and the honest version is worth knowing.

The largest trial was BILCAP, in the United Kingdom. It enrolled 447 people who had a complete removal of cholangiocarcinoma or muscle-invasive gallbladder cancer. Half received eight cycles of capecitabine tablets twice a day, on days 1 to 14 of each 21-day cycle, at a strength calculated from body size. Half were observed.

At a median follow-up of 106 months:

• Median overall survival was 49.6 months with capecitabine and 36.1 months with observation.
• That difference was not statistically significant in the main analysis. The adjusted hazard ratio was 0.84, with a confidence interval of 0.67 to 1.06.
• Median recurrence-free survival was 24.3 months with capecitabine and 17.4 months with observation.

NCI's summary puts it plainly. Randomized trials have not consistently shown a clear survival gain from adjuvant chemotherapy. Capecitabine is still widely used. The reasoning behind it is a fair thing to ask about.

A blocked bile duct causes jaundice, itching, and a risk of infection. Relieving it is separate from treating the cancer, and it can be done at any stage. Three approaches are used:

• Endoscopic stent placement. A thin flexible tube is placed through the blockage. It drains bile into the small intestine, or out to a bag.
• Biliary bypass. Surgery cuts the duct or gallbladder above the blockage. It is then sewn to the duct beyond the blockage, or to the small intestine. That creates a new route.
• Percutaneous transhepatic biliary drainage. A needle passes through the skin below the ribs into the liver. Dye is injected and an x-ray is taken. A stent can be left behind to drain bile.

Most people with bile duct cancer cannot have it fully removed. The backbone of treatment there is chemotherapy, and one trial set that standard.

ABC-02 randomly assigned 410 people with unresectable, recurrent, or metastatic biliary tract cancer to cisplatin plus gemcitabine, or gemcitabine alone, for up to six months. Median overall survival was 11.7 months with the two-drug combination and 8.1 months with gemcitabine alone. The hazard ratio was 0.64.

Two later trials added an immunotherapy drug on top of that pair:

• TOPAZ-1 enrolled 685 people and added durvalumab or placebo. Median overall survival was 12.9 months with durvalumab and 11.3 months with placebo. At 24 months, 24.9% of the durvalumab group were alive, against 10.4% of the placebo group.
• KEYNOTE-966 enrolled 1,069 people and added pembrolizumab or placebo. Median overall survival was 12.7 months with pembrolizumab and 10.9 months with placebo.

NCI now calls this the standard of care for first-line treatment. Add a checkpoint inhibitor, either durvalumab or pembrolizumab, to cisplatin and gemcitabine. Other options exist. They include gemcitabine with capecitabine, GEMOX, XELOX, and fluorouracil with liposomal irinotecan.

Bile duct cancer is one of the cancers where testing the tumor's genes can open specific doors. Ask directly whether your tumor has been tested. Our page on biomarker testing explains how the tests work.

IDH1 variants. The ClarIDHy trial enrolled 187 people whose cancer had progressed on earlier treatment. Median progression-free survival was 2.7 months with ivosidenib and 1.4 months with placebo. At six months, no one in the placebo group was progression free.

FGFR2 fusions or rearrangements. Two drugs are relevant:

• Pemigatinib, a tablet taken once a day for 14 days, then 7 days off. In the FIGHT-202 trial, the response rate among 108 people with FGFR2 rearrangements was 37%, with a median response duration of 9.1 months. FDA granted accelerated approval in 2020. High blood phosphate occurred in 58.5% of patients.
• Futibatinib, a tablet taken once a day without a break. In FOENIX-CCA2, with 103 patients, the response rate was 42% and median overall survival was 21.7 months. High blood phosphate occurred in 85%, and was severe in 30%.

HER2. Zanidatamab-hrii, sold as Ziihera, won FDA accelerated approval on November 20, 2024. It is for adults with previously treated bile duct or other biliary tract cancer that cannot be removed or has spread. The tumor must be HER2-positive at IHC 3+, shown by an FDA-approved test. It goes in by vein every 2 weeks, in an amount scaled to body weight by the pharmacy. Three drugs are given 30 to 60 minutes before each infusion: acetaminophen, an antihistamine, and a corticosteroid. They cut the risk of infusion reactions.

Mismatch repair. People whose tumors are dMMR or MSI-high may be candidates for pembrolizumab even if they have not had a checkpoint inhibitor before.

A liver transplant removes the whole liver and replaces it with a donated one. NCI lists it as an option for some people with perihilar bile duct cancer. Other treatment is given while waiting for a donor organ. It applies to a small, carefully selected group, so it is worth asking directly whether your situation could qualify.

NCI states plainly that all patients should consider clinical trials, and that people with FGFR2 fusion-positive or HER2-amplified disease in particular are candidates. That is not a fallback. In this cancer, trials are where several current standards came from. See clinical trial versus standard treatment for how the choice actually works.

• National Cancer Institute, Bile Duct Cancer Treatment, updated May 24, 2024; accessed August 6, 2026
• National Cancer Institute, Bile Duct Cancer Treatment PDQ, health professional version, updated March 28, 2025; accessed August 6, 2026
• U.S. Food and Drug Administration, Drugs@FDA record for Ziihera (zanidatamab-hrii), BLA 761416, accessed August 6, 2026
• DailyMed, Ziihera (zanidatamab-hrii) prescribing information, accessed August 6, 2026